---
layout: post
title: "上海阳性感染者中药使用率超98% 板块掀涨停潮 14只股获北向资金加仓"
date: 2022-04-06 18:16:57 +0800
categories: emnews
tags: 东财滚动新闻
---
> 中药板块今日表现强势，有10股涨停，瑞康医药3连板，海南海药2连板，大理药业、益盛药业、启迪药业、以岭药业等股涨停。今年以来，盘龙药业的股价累计上涨139.58%，青海春天、精华制药、以岭药业、振东制药的股价累计涨幅均超50%。（证券时报）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" data-code="BK1040|90|1" data-code2="BK1040|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1040&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1040_0" data-code="K BK1040|90|1" data-code2="K BK1040|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p><span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>板块表现强势，多家公司产品被列入新版新冠诊疗方案。<br /></p><p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块多股涨停</strong></p><p><span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块今日表现强势，有10股涨停，<strong><span id="stock_0.002589"><a href="http://quote.eastmoney.com/unify/r/0.002589" class="keytip" data-code="0,002589">瑞康医药</a></span><span id="quote_0.002589"></span></strong>3连板，<strong><span id="stock_0.000566"><a href="http://quote.eastmoney.com/unify/r/0.000566" class="keytip" data-code="0,000566">海南海药</a></span><span id="quote_0.000566"></span></strong>2连板，<strong><span id="stock_1.603963"><a href="http://quote.eastmoney.com/unify/r/1.603963" class="keytip" data-code="1,603963">大理药业</a></span><span id="quote_1.603963"></span>、<span id="stock_0.002566"><a href="http://quote.eastmoney.com/unify/r/0.002566" class="keytip" data-code="0,002566">益盛药业</a></span><span id="quote_0.002566"></span>、<span id="stock_0.000590"><a href="http://quote.eastmoney.com/unify/r/0.000590" class="keytip" data-code="0,000590">启迪药业</a></span><span id="quote_0.000590"></span>、<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span></strong>等股涨停。</p><p>今年以来，<strong><span id="stock_0.002864"><a href="http://quote.eastmoney.com/unify/r/0.002864" class="keytip" data-code="0,002864">盘龙药业</a></span><span id="quote_0.002864"></span></strong>的股价累计上涨139.58%，<strong><span id="stock_1.600381"><a href="http://quote.eastmoney.com/unify/r/1.600381" class="keytip" data-code="1,600381">青海春天</a></span><span id="quote_1.600381"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>、<span id="stock_0.300158"><a href="http://quote.eastmoney.com/unify/r/0.300158" class="keytip" data-code="0,300158">振东制药</a></span><span id="quote_0.300158"></span></strong>的股价累计涨幅均超50%。</p><p>消息面上，世界卫生组织关于中医药治疗新冠肺炎专家评估会的报告于3月31日在世卫组织官网发布，来自世卫组织6个区域的21名国际专家参加了评估会，会议报告指出：<strong>中药能有效治疗新冠肺炎，降低轻型、普通型病例转为重症，缩短病毒清除时间，改善轻型和普通型患者的临床预后</strong>。报告同时鼓励成员国考虑中国形成并应用的整合医学模式(中西医结合模式)；有效管理当前疫情并对未来可能发生的大流行做好准备。</p><p><strong>上海阳性感染者中药使用率98%以上</strong></p><p>随着上海等地疫情的出现，中药在其中的应用也越来越受到重视。据央视新闻报道，在4月5日举行的上海市疫情防控工作新闻发布会上，上海中医药大学附属曙光医院院长、中医疫病防治基地负责人房敏表示<strong>中医药在新冠疫情防控中发挥了积极作用，上海针对阳性感染者，中药使用率稳定保持在98%以上。</strong></p><p>3月初，上海市卫健委、上海市中医药管理局发布了由国家中医疫病防治基地制定的《2022年春季易感人群外感疫病中药内服预防方案》，向隔离点及重点封控的街镇、小区、楼宇人群提供中药预防方药，深受群众欢迎。在此基础上，开展面向全市全人群、全覆盖的中医药预防干预工作，目前已累计向各街镇配送超过2100万人份中药预防方药，对尽快建立防疫屏障起到了积极作用。</p><p>此外， 3月14日，国家卫健委、国家中医药管理局再次联合发布《新型冠状病毒肺炎诊疗方案(试行第九版)》，就突出了中医药治疗，就诊疗各阶段提出了相应中医药诊疗方案。</p><p>具体到上市公司方面，<strong><span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span></strong>的血必净注射液、<strong><span id="stock_1.603858"><a href="http://quote.eastmoney.com/unify/r/1.603858" class="keytip" data-code="1,603858">步长制药</a></span><span id="quote_1.603858"></span></strong>的宣肺败毒颗粒、<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span></strong>的连花清瘟胶囊(颗粒)、<strong><span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span></strong>的藿香正气口服液等产品被列入新型冠状病毒肺炎诊疗方案(试行第九版)。</p><p><strong>多股获北向资金加仓</strong></p><p>首创<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>指出，在新冠疫情之中，中医药发挥了重大作用，近年来随着高层对中医药事业的重视程度不断提升，各类支持中医药发展的政策陆续出台。特别是在2020-2021年，中医药行业利好政策密集出台，<strong>涉及到药品审评、临床使用、医保支付、<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>体系建设等诸多方面，中医药行业政策环境大幅度好转，行业有望迎来拐点。</strong></p><p><span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>时报·数据宝统计，板块中<strong><span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_1.600436"><a href="http://quote.eastmoney.com/unify/r/1.600436" class="keytip" data-code="1,600436">片仔癀</a></span><span id="quote_1.600436"></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="stock_0.000423"><a href="http://quote.eastmoney.com/unify/r/0.000423" class="keytip" data-code="0,000423">东阿阿胶</a></span><span id="quote_0.000423"></span>、以岭药业</strong>等9股均有5家以上机构评级。</p><p>资金面上，14股获北向资金青睐。3月以来，<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.000423" class="em_stock_key_common" data-code="0,000423">东阿阿胶</span>、<span id="stock_1.600332"><a href="http://quote.eastmoney.com/unify/r/1.600332" class="keytip" data-code="1,600332">白云山</a></span><span id="quote_1.600332"></span>、以岭药业、<span id="stock_1.600993"><a href="http://quote.eastmoney.com/unify/r/1.600993" class="keytip" data-code="1,600993">马应龙</a></span><span id="quote_1.600993"></span>、<span id="stock_1.600285"><a href="http://quote.eastmoney.com/unify/r/1.600285" class="keytip" data-code="1,600285">羚锐制药</a></span><span id="quote_1.600285"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300026" class="em_stock_key_common" data-code="0,300026">红日药业</span>、<span id="stock_1.600252"><a href="http://quote.eastmoney.com/unify/r/1.600252" class="keytip" data-code="1,600252">中恒集团</a></span><span id="quote_1.600252"></span></strong>等14股的获得<span id="Info.3314"><a href="http://data.eastmoney.com/hsgt/index.html" class="infokey">北上资金</a></span>累计净买入；<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.000423" class="em_stock_key_common" data-code="0,000423">东阿阿胶</span></strong>的北上资金累计净买入额最多，为6.48亿元。</p><p>数据宝统计，<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>方面，按照年报或预告下限计算，<strong><span id="stock_1.600518"><a href="http://quote.eastmoney.com/unify/r/1.600518" class="keytip" data-code="1,600518">*ST康美</a></span><span id="quote_1.600518"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600332" class="em_stock_key_common" data-code="1,600332">白云山</span>、<span id="stock_0.000538"><a href="http://quote.eastmoney.com/unify/r/0.000538" class="keytip" data-code="0,000538">云南白药</a></span><span id="quote_0.000538"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300158" class="em_stock_key_common" data-code="0,300158">振东制药</span></strong>等7股的2021年归母<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>额超20亿元，<strong>东阿阿胶、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300158" class="em_stock_key_common" data-code="0,300158">振东制药</span>、<span id="stock_1.600572"><a href="http://quote.eastmoney.com/unify/r/1.600572" class="keytip" data-code="1,600572">康恩贝</a></span><span id="quote_1.600572"></span>、<span id="stock_0.002773"><a href="http://quote.eastmoney.com/unify/r/0.002773" class="keytip" data-code="0,002773">康弘药业</a></span><span id="quote_0.002773"></span>、<span id="stock_1.600538"><a href="http://quote.eastmoney.com/unify/r/1.600538" class="keytip" data-code="1,600538">国发股份</a></span><span id="quote_1.600538"></span></strong>等14股的业绩同比翻倍增长。</p><p>有3股已经抢先发布了今年一季度的业绩预告，<strong><span id="stock_0.300181"><a href="http://quote.eastmoney.com/unify/r/0.300181" class="keytip" data-code="0,300181">佐力药业</a></span><span id="quote_0.300181"></span>、<span id="stock_1.600750"><a href="http://quote.eastmoney.com/unify/r/1.600750" class="keytip" data-code="1,600750">江中药业</a></span><span id="quote_1.600750"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600436" class="em_stock_key_common" data-code="1,600436">片仔癀</span></strong>均预增。</p><center><img src="https://dfscdn.dfcfw.com/download/D24973171543701230683_w770h560.jpg" alt="Image" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>时报）</p>

<http://finance.eastmoney.com/news/1353,202204062333784678.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)